MCID: DBT005
MIFTS: 54

Diabetes Insipidus

Categories: Endocrine diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Diabetes Insipidus

MalaCards integrated aliases for Diabetes Insipidus:

Name: Diabetes Insipidus 12 75 29 6 43 44 15 72 33

Classifications:



External Ids:

Disease Ontology 12 DOID:9409
ICD9CM 35 253.5
MeSH 44 D003919
NCIt 50 C43263
SNOMED-CT 68 15771004
ICD10 33 E23.2
UMLS 72 C0011848

Summaries for Diabetes Insipidus

MedlinePlus : 43 Diabetes insipidus (DI) causes frequent urination. You become extremely thirsty, so you drink. Then you urinate. This cycle can keep you from sleeping or even make you wet the bed. Your body produces lots of urine that is almost all water. DI is different from diabetes mellitus (DM), which involves insulin problems and high blood sugar. The symptoms can be similar. However, DI is related to how your kidneys handle fluids. It's much less common than DM. Urine and blood tests can show which one you have. Usually, DI is caused by a problem with your pituitary gland or your kidneys. Treatment depends on the cause of the problem. Medicines can often help. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diabetes Insipidus is related to diabetes insipidus, nephrogenic, x-linked and wolfram syndrome 1. An important gene associated with Diabetes Insipidus is AVP (Arginine Vasopressin), and among its related pathways/superpathways are Neuroscience and Glucose / Energy Metabolism. The drugs Dexmedetomidine and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and kidney, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 75 Diabetes insipidus (DI) is a condition characterized by large amounts of dilute urine and increased... more...

Related Diseases for Diabetes Insipidus

Diseases in the Diabetes Insipidus family:

Hereditary Central Diabetes Insipidus Acquired Central Diabetes Insipidus
Congenital Central Diabetes Insipidus

Diseases related to Diabetes Insipidus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 894)
# Related Disease Score Top Affiliating Genes
1 diabetes insipidus, nephrogenic, x-linked 35.4 AVPR2 AQP2
2 wolfram syndrome 1 34.3 WFS1 AVP
3 wolfram syndrome 34.2 WFS1 CISD2 AVP
4 diabetes insipidus, nephrogenic, autosomal 34.0 SLC12A1 CLCNKA AVPR2 AVP ARHGAP4 AQP2
5 diabetes insipidus, neurohypophyseal 33.5 PRL POMC AVPR2 AVP AQP2
6 wolfram syndrome 2 32.9 WFS1 CISD2
7 nephrogenic syndrome of inappropriate antidiuresis 31.0 AVPR2 AVP
8 secondary adrenal insufficiency 30.9 INS AVP
9 central nervous system germinoma 30.7 POMC AVP
10 syndrome of inappropriate antidiuretic hormone 30.6 POMC AVPR2 AVP AQP2
11 polycystic kidney disease 30.5 REN AVPR2 AQP2
12 bartter disease 30.5 SLC12A1 REN CLCNKA
13 lung oat cell carcinoma 30.5 POMC AVP
14 pituitary hormone deficiency, combined, 2 30.3 PRL POMC AVP
15 empty sella syndrome 30.3 PRL POMC
16 cardiac tamponade 30.2 REN AVP
17 liver cirrhosis 30.2 REN AVP AQP2
18 familial glucocorticoid deficiency 30.2 REN POMC
19 hypoadrenalism 30.2 POMC CRH
20 hypokalemia 30.2 SLC12A1 REN POMC AQP2
21 idiopathic edema 30.1 INS AQP2
22 adenohypophysitis 30.0 PRL POMC
23 acute adrenal insufficiency 29.9 REN POMC
24 hypoaldosteronism 29.9 REN POMC
25 autosomal dominant polycystic kidney disease 29.7 REN AVPR2 AVP AQP2
26 amenorrhea 29.6 PRL POMC CRH
27 pituitary apoplexy 29.6 PRL POMC INS
28 pituitary infarct 29.6 PRL POMC
29 inappropriate adh syndrome 29.5 REN POMC AVPR2 AVP AQP2
30 hypopituitarism 29.5 PRL POMC INS CRH
31 melancholia 29.4 PRL CRH
32 acromegaly 29.4 PRL POMC INS
33 abducens nerve disease 29.2 PRL POMC
34 adrenal adenoma 29.2 REN POMC CRH
35 hypothalamic disease 28.9 PRL POMC CRH
36 anorexia nervosa 28.8 PRL POMC CRH
37 pituitary gland disease 28.8 PRL POMC INS CRH AVP
38 chromophobe adenoma 28.7 PRL POMC INS AVP
39 sheehan syndrome 28.6 PRL POMC INS CRH
40 conn's syndrome 28.3 REN PRL POMC CRH
41 major depressive disorder 28.0 PRL POMC CRH
42 hereditary central diabetes insipidus 12.6
43 diabetes insipidus, nephrogenic, with mental retardation and intracerebral calcification 12.6
44 acquired central diabetes insipidus 12.6
45 gestational diabetes insipidus 12.6
46 dipsogenic diabetes insipidus 12.5
47 congenital central diabetes insipidus 12.5
48 hypopituitarism, congenital, with central diabetes insipidus 12.5
49 x-linked intellectual disability-limb spasticity-retinal dystrophy-diabetes insipidus syndrome 12.3
50 obsolete: posttraumatic diabetes insipidus 12.3

Comorbidity relations with Diabetes Insipidus via Phenotypic Disease Network (PDN):


Acute Cystitis Diabetes Insipidus, Nephrogenic, Autosomal
Hypothyroidism Pituitary Hormone Deficiency, Combined, 2

Graphical network of the top 20 diseases related to Diabetes Insipidus:



Diseases related to Diabetes Insipidus

Symptoms & Phenotypes for Diabetes Insipidus

MGI Mouse Phenotypes related to Diabetes Insipidus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.11 AQP2 AVP AVPR2 CISD2 CRH INS
2 homeostasis/metabolism MP:0005376 10.03 AQP2 AVP AVPR2 CISD2 CLCNKA CRH
3 growth/size/body region MP:0005378 10.02 AQP2 AVPR2 CISD2 CLCNKA CRH INS
4 integument MP:0010771 9.81 AQP2 AVPR2 CISD2 CRH INS POMC
5 mortality/aging MP:0010768 9.65 AQP2 AVP AVPR2 CISD2 CLCNKA INS
6 renal/urinary system MP:0005367 9.32 AQP2 AVP AVPR2 CISD2 CLCNKA CRH

Drugs & Therapeutics for Diabetes Insipidus

Drugs for Diabetes Insipidus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 129)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
2
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
3
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
4
Tolvaptan Approved Phase 4 150683-30-0 216237
5 Analgesics Phase 4
6 Anti-Inflammatory Agents Phase 4
7 Analgesics, Non-Narcotic Phase 4
8 Peripheral Nervous System Agents Phase 4
9 Central Nervous System Depressants Phase 4
10 Neurotransmitter Agents Phase 4
11 Adrenergic Agents Phase 4
12 Anesthetics Phase 4
13 Adrenergic alpha-2 Receptor Agonists Phase 4
14 Adrenergic Agonists Phase 4
15 Adrenergic alpha-Agonists Phase 4
16 Hypnotics and Sedatives Phase 4
17 Hydrocortisone-17-butyrate Phase 4
18 Hydrocortisone 17-butyrate 21-propionate Phase 4
19 Hydrocortisone hemisuccinate Phase 4
20 Deamino Arginine Vasopressin Phase 4
21 Pharmaceutical Solutions Phase 4
22 Hormones Phase 4
23 diuretics Phase 4
24 Antidiuretic Hormone Receptor Antagonists Phase 4
25 Sodium Potassium Chloride Symporter Inhibitors Phase 4
26
Satavaptan Investigational Phase 3 185913-78-4 7029
27 Hormone Antagonists Phase 3
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
29
tannic acid Approved Phase 2 1401-55-4
30
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
31
Lithium carbonate Approved Phase 2 554-13-2
32
Atorvastatin Approved Phase 2 134523-00-5 60823
33
Dantrolene Approved, Investigational Phase 1, Phase 2 7261-97-4 2952 6914273
34
Dulaglutide Approved, Investigational Phase 2 923950-08-7
35 Natriuretic Agents Phase 1, Phase 2
36 Coagulants Phase 1, Phase 2
37 Hemostatics Phase 1, Phase 2
38 arginine Phase 1, Phase 2
39 Vasopressins Phase 1, Phase 2
40 Vasoconstrictor Agents Phase 1, Phase 2
41 Arginine Vasopressin Phase 1, Phase 2
42 Hypoglycemic Agents Phase 2
43 Lipid Regulating Agents Phase 2
44 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
45 Hypolipidemic Agents Phase 2
46 Anticholesteremic Agents Phase 2
47 Antimetabolites Phase 2
48 Glucagon-Like Peptide 1 Phase 2
49 Neuromuscular Agents Phase 1, Phase 2
50
Metformin Approved Phase 1 657-24-9 4091 14219

Interventional clinical trials:

(show top 50) (show all 90)
# Name Status NCT ID Phase Drugs
1 Effect of Dexmedetomidine as Anesthetic Coadjuvant on Plasmatic Cortisol Response in Transsphenoidal Surgery for Pituitary Tumors Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
2 Pilot Study of the Relationship of Ambient Copeptin to the Aquaretic Effects of Tolvaptan in Patients With Heart Failure Completed NCT01346072 Phase 4 tolvaptan
3 1-deamino 8-d-arginine Vasopressin in Percutaneous Ultrasound-guided Renal Biopsy: a Randomized Controlled Trial Completed NCT00748072 Phase 4 DDAVP;saline solution
4 Desmopressin in the Treatment of Mixed Nocturia With Nocturnal Polyuria and Low Nocturnal Bladder Capacity Completed NCT00902655 Phase 4 Desmopressin
5 Tolvaptan Treatment to Reverse Worsening Outpatient Heart Failure: Possible Role of Copeptin In Identifying Responders (TROUPER) Recruiting NCT02476409 Phase 4 tolvaptan
6 Acute Heart Failure With High Copeptin Levels Treated With Tolvaptan Targets Increased AVP Activation for Treatment Efficacy Unknown status NCT01733134 Phase 3 Tolvaptan;placebo
7 A CLINICAL STUDY TO EVALUATE THE EFFICACY OF CAUSTICUM 200C IN THE TREATMENT OF PRIMARY ENURESIS Unknown status NCT02154152 Phase 3 Homoeopathic Medicine causticum 200c
8 Peroral Administration of Different Doses of Desmopressin Administered as a New Orally-Disintegrating Tablet and Desmopressin for Nasal Administration in the Treatment of CDI in Japanese Patients Completed NCT01280188 Phase 3 Desmopressin Oral Melt;Desmopressin intranasal
9 A Randomized, Double-Blind, Placebo-Group, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT00264927 Phase 3 SR121463B
10 An Open-Label, Multicenter Study Evaluating the Long-Term Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT00264914 Phase 3 SR121463B
11 A Multicenter, Uncontrolled, Open-label, Dose-titration Trial to Investigate the Efficacy and Safety of Tolvaptan Tablets in Patients With Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Recruiting NCT03048747 Phase 3 Tolvaptan Oral Tablet
12 A Phase 1b, Multicenter, Pilot, Randomized, Double-blind Trial to Determine the Pharmacokinetics and Pharmacodynamics of Orally Administered Tolvaptan 3.75, 7.5, and 15 mg Tablets in Subjects With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT02009878 Phase 1, Phase 2 tolvaptan
13 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion. Completed NCT00032734 Phase 2 satavaptan (SR121463B)
14 Efficacy and Pharmacokinetics of Oral Thyroid Replacement Therapy in Organ Donors Completed NCT00238030 Phase 1, Phase 2 L-thryoxine;iv thryoxine
15 A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose Range Finding Study To Determine The Efficacy And Safety Of Fedovapagon In Men With Nocturia Completed NCT01656239 Phase 2 fedovapagon 1 mg;fedovapagon 2 mg;fedovapagon 4 mg;Placebo ( sugar pill)
16 AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock Completed NCT01611935 Phase 2 Vasopressin
17 Effects of Glucose Containing Fluid in the Treatment of Acute Dehydration Completed NCT01285713 Phase 2 5% Dextrose (D5) in Normal Saline (NS);Normal Saline (NS)
18 Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus: A Randomized Controlled Trial Recruiting NCT02967653 Phase 2 Atorvastatin
19 A Phase 1b Safety Trial of Dantronele Sodium in Pediatric and Adult Patients With Wolfram Syndrome Recruiting NCT02829268 Phase 1, Phase 2 dantrolene sodium
20 Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia: "The GOLD-Study" Recruiting NCT02770885 Phase 2 Dulaglutide;Placebo
21 The Influence of Vasopressin on Observational Learning of Placebo Analgesia Recruiting NCT03446456 Phase 1, Phase 2 Arginine vasopressin
22 A Randomised, Double-blind, Placebo-controlled, Five-way Cross-over Dose Response Study to Determine the Effect of VA106483 on Nocturnal Urine Volume in Elderly Male Subjects With Nocturia and Benign Prostatic Hypertrophy (BPH) Completed NCT01330927 Phase 1 VA106483
23 Use of Metformin to Treat Patients With Congenital Nephrogenic Diabetes Insipidus (NDI) Terminated NCT02460354 Phase 1 Metformin
24 Study of Novel Types of Familial Diabetes Insipidus Unknown status NCT00004364 desmopressin
25 GLP Analogs for Diabetes in Wolfram Syndrome Patients Unknown status NCT01302327 Exenatide
26 Diagnostic Utility of Copeptin in Addition to High-sensitivity Cardiac Troponin for the Early Diagnosis of Non-ST-Elevation Acute Coronary Syndromes - The COPACS Study Unknown status NCT01962506
27 CARDIOVASCULAR RISK FACTORS IN ADULT PATIENTS WITH MULTISYSTEM LANGERHANS-CELL HISTIOCYTOSIS: EVIDENCE OF GLUCOSE METABOLISM ABNORMALITIES Unknown status NCT00483925
28 Copeptin in the Diagnosis and Differential Diagnosis of Diabetes Insipidus. The CoSIP-Study Completed NCT00757276
29 Copeptin After Arginine Infusion for the Differential Diagnosis of the Polyuria-Polydipsia Syndrome ''The CARGO-Study'' Completed NCT01879137
30 Use of Copeptin in the Differential Diagnosis of Diabetes insipidus-a Prospective International Study Completed NCT01940614
31 Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus Completed NCT00004360 chlorothiazide
32 Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed NCT00004363 chlorpropamide;desmopressin
33 Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis Completed NCT01465672
34 Copeptin During a Standardized Oral Glucose Tolerance Test and a Mixed Meal Tolerance Test Completed NCT01772914
35 Copeptin During a Standardized Psychological Stress Test Completed NCT01866137
36 GE DHM-AN-OR-2012/01 Completed NCT01648647
37 Kinetics of Copeptin in Healthy Volunteers - a Prospective International Study Completed NCT02647736
38 The Circadian Rhythm of Copeptin Completed NCT02604875
39 Copeptin as a Stress Marker During a Written Examination - the CoEXAM Completed NCT02051647
40 Copeptin in Differentiation of Polyuria and Polydipsia Completed NCT01056887
41 Assessment of Circulating Copeptin Levels in Healthy Subjects and Patients With Renal Insufficiency After Oral Water Load and Hypertonic Saline Infusion Completed NCT00696605
42 Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers - The Macicop-Study Completed NCT03844217 Macimorelin 0.5mg/kg body weight;Macimorelin 0.75mg/kg body weight
43 Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus Completed NCT00478335 sildenafil;calcitonin;hydrochlorothiazide/amiloride;indomethacin;Placebo for sildenafil;placebo for calcitonin
44 Vasopressin Deficiency in Hemorrhagic Shock Completed NCT01107314
45 The Influence of Water and Salt Intake on Copeptin Levels During Moderate Alcohol Consumption - a Pathophysiological Study Completed NCT03883503
46 The Role of Copeptin Testing During Pre-hospital Care in the Treatment of Chest Pain Suggestive of Acute Coronary Syndrome Completed NCT02116426
47 Spectrum of Serum Sodium Disturbances in Patients With Non-sellar/Suprasellar Supratentorial Tumors Completed NCT03570203
48 Alpha-blocker Plus Diuretic Combination Therapy as Second-line Treatment for Nocturia in Men With LUTS: a Pilot Study Completed NCT00700583 combination therapy of terazosin and hydrochlorothiazide
49 Study of Prognosis Value of Protein S100Beta and Copeptine in Seizure in the Emergency Department Completed NCT01774500
50 Copeptin Pancreatitis Trial Completed NCT01293318

Search NIH Clinical Center for Diabetes Insipidus

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Chlorpropamide
desmopressin
Desmopressin Acetate
Hydrochlorothiazide
Vasopressin (USP)
VASOPRESSIN TANNATE (IN OIL)

Cochrane evidence based reviews: diabetes insipidus

Genetic Tests for Diabetes Insipidus

Genetic tests related to Diabetes Insipidus:

# Genetic test Affiliating Genes
1 Diabetes Insipidus 29

Anatomical Context for Diabetes Insipidus

MalaCards organs/tissues related to Diabetes Insipidus:

41
Pituitary, Brain, Kidney, Testes, Lung, Thyroid, Bone

Publications for Diabetes Insipidus

Articles related to Diabetes Insipidus:

(show top 50) (show all 8236)
# Title Authors PMID Year
1
PITUITARY STALK THICKENING IN A LARGE COHORT: TOWARD MORE ACCURATE PREDICTORS OF PITUITARY DYSFUNCTION AND ETIOLOGY. 38 17
30865546 2019
2
A novel AVPR2 missense mutation in an Asian family with inherited nephrogenic diabetes insipidus: A case report. 38 17
31027113 2019
3
Renal Tubular Acidosis Presenting as Nephrogenic Diabetes Insipidus. 38 17
31064905 2019
4
A novel SLC12A1 mutation in Bedouin kindred with antenatal Bartter syndrome type I. 38
30977917 2019
5
Other Pituitary Conditions and Pregnancy. 38
31345525 2019
6
Benefit of Intracystic Bleomycin for Symptomatic Recurrent Rathke Cleft Cyst. 38
30445570 2019
7
Intraoperative MRI in transsphenoidal resection of invasive pituitary macroadenomas. 38
30949920 2019
8
Small molecules for modulating the localisation of the water channel aquaporin-2-disease relevance and perspectives for targeting local cAMP signalling. 38
31300862 2019
9
Pineal region tumors: Long-term results of endoscopic third ventriculostomy and concurrent tumor biopsy with a single entry approach in a series of 64 cases. 38
31319237 2019
10
Pituitary involvement in patients with granulomatosis with polyangiitis: case series and literature review. 38
31203400 2019
11
Novel mutations and the ophthalmologic characters in Chinese patients with Wolfram Syndrome. 38
31391115 2019
12
Preservation of hypothalamic function with endoscopic endonasal resection of hypothalamus-invaded craniopharyngiomas. 38
31398519 2019
13
Etiological Spectrum and Pattern of Change in Pituitary Stalk Thickening: Experience in 321 Patients. 38
30892632 2019
14
Pituitary Metastases: A Nationwide Study on Current Characteristics With Special Reference to Breast Cancer. 38
30892659 2019
15
Sleep disturbances in Wolfram syndrome. 38
31375124 2019
16
Low Plasma Oxytocin Levels and Increased Psychopathology in Hypopituitary Men With Diabetes Insipidus. 38
30882859 2019
17
Reasons Why Organs From Deceased Donors Were Not Accepted for Transplantation. 38
31378471 2019
18
Clinical approach to sodium homeostasis disorders in children with pituitary-suprasellar tumors. 38
31401632 2019
19
Autoimmune phenomena involving the pituitary gland in children: New developing data about diagnosis and treatment. 38
31401342 2019
20
Peel-off resection of the pituitary gland for functional pituitary adenomas: pathological significance and impact on pituitary function. 38
31377966 2019
21
Response to Letter to the Editor: "Predictors of Postoperative Diabetes Insipidus Following Endoscopic Resection of Pituitary Adenomas". 38
31342004 2019
22
Surgical outcome of endoscopic endonasal surgery of large and giant pituitary adenomas: An institutional experience from the Middle East. 38
31404693 2019
23
Letter to the Editor: "Predictors of Postoperative Diabetes Insipidus Following Endoscopic Resection of Pituitary Adenomas". 38
31342003 2019
24
Expanded Endonasal Endoscopic Surgery in Suprasellar Craniopharyngiomas: A Retrospective Analysis of 43 Surgeries Including Recurrent Cases. 38
30768130 2019
25
Withholding Perioperative Steroids in Patients Undergoing Transsphenoidal Resection for Pituitary Disease: Randomized Prospective Clinical Trial to Assess Safety. 38
30325449 2019
26
Generalized eruptive histiocytoma developing into xanthoma disseminatum with central diabetes insipidus. 38
30859591 2019
27
Diabetes insipidus. 38
31395882 2019
28
Diabetes insipidus. 38
31395885 2019
29
Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. 38
31303316 2019
30
Autosomal dominant familial neurohypophyseal diabetes insipidus caused by a novel nonsense mutation in AVP-NPII gene. 38
31316622 2019
31
RNA-Seq and protein mass spectrometry in microdissected kidney tubules reveal signaling processes initiating lithium-induced nephrogenic diabetes insipidus. 38
31146973 2019
32
Contiguous gene deletion in a Chinese family with X-linked nephrogenic diabetes insipidus: challenges in early diagnosis and implications for affected families. 38
31271558 2019
33
Segregation of two variants suggests the presence of autosomal dominant and recessive forms of WFS1-related disease within the same family: expanding the phenotypic spectrum of Wolfram Syndrome. 38
31363008 2019
34
Clinical and molecular assessment of 13 Iranian families with Wolfram syndrome. 38
31313226 2019
35
Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives. 38
31337416 2019
36
An Extended Endoscopic Endonasal Approach for Sellar Area Chondrosarcoma: A Case Report and Literature Review. 38
30995554 2019
37
A novel missense mutation in TFAP2B associated with Char syndrome and central diabetes insipidus. 38
31012281 2019
38
Hydranencephaly complicated by central diabetes insipidus: report of two cases and systematic review of literature. 38
30929071 2019
39
Combined Inhibitory Effects of Citrinin, Ochratoxin-A, and T-2 Toxin on Aquaporin-2. 38
31204482 2019
40
Copeptin in the differential diagnosis of hypotonic polyuria. 38
31368050 2019
41
Copeptin and its role in the diagnosis of diabetes insipidus and the syndrome of inappropriate antidiuresis. 38
31004513 2019
42
Endocrine and Visual Outcomes Following Gross Total Resection and Subtotal Resection of Adult Craniopharyngioma: Systematic Review and Meta-Analysis. 38
30947004 2019
43
Sixty years single institutional experience with pediatric craniopharyngioma: between the past and the future. 38
31292757 2019
44
A regional Australasian experience of extended endoscopic transsphenoidal surgery for craniopharyngioma: Progression of the mentoring model. 38
31303398 2019
45
Intracranial germinoma masquerading as secondary granulomatous hypophysitis: A case report and review of literature. 38
31269501 2019
46
A cost of illness study evaluating the burden of Wolfram syndrome in the United Kingdom. 38
31366393 2019
47
Endocrine manifestations in a cohort of 63 adulthood and childhood onset patients with Langerhans Cell Histiocytosis. 38
31269469 2019
48
Langerhans' cell histiocytosis of the temporal bone in an adult with central diabetes insipidus. 38
31080537 2019
49
[Minimal change disease during lithium therapy: case report]. 38
31373471 2019
50
ENDOCRINOLOGY AND ADOLESCENCE: Dealing with transition in young patients with pituitary disorders. 38
31370006 2019

Variations for Diabetes Insipidus

ClinVar genetic disease variations for Diabetes Insipidus:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 MATN4 NM_003833.4(MATN4): c.515G> C (p.Gly172Ala) single nucleotide variant Likely pathogenic rs730882210 20:43932996-43932996 20:45304356-45304356

Expression for Diabetes Insipidus

Search GEO for disease gene expression data for Diabetes Insipidus.

Pathways for Diabetes Insipidus

GO Terms for Diabetes Insipidus

Cellular components related to Diabetes Insipidus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.63 REN PRL POMC INS CRH AVP
2 endosome lumen GO:0031904 8.96 PRL INS
3 secretory granule GO:0030141 8.62 POMC AVP

Biological processes related to Diabetes Insipidus according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.76 INS CRH AVPR2 AVP
2 positive regulation of cell proliferation GO:0008284 9.55 PRL INS CRH AVPR2 AVP
3 glucose homeostasis GO:0042593 9.54 WFS1 POMC INS
4 positive regulation of vasoconstriction GO:0045907 9.49 AVPR2 AVP
5 response to immobilization stress GO:0035902 9.48 REN CRH
6 water transport GO:0006833 9.43 AVP AQP2
7 response to ethanol GO:0045471 9.4 CRH AVP
8 positive regulation of systemic arterial blood pressure GO:0003084 9.26 AVPR2 AVP
9 parturition GO:0007567 9.02 CRH
10 excretion GO:0007588 8.96 CLCNKA AVPR2
11 renal water homeostasis GO:0003091 8.92 WFS1 AVPR2 AVP AQP2

Molecular functions related to Diabetes Insipidus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.46 REN POMC CRH AVP
2 neuropeptide hormone activity GO:0005184 9.26 CRH AVP
3 hormone activity GO:0005179 9.02 PRL POMC INS CRH AVP
4 insulin-like growth factor receptor binding GO:0005159 8.96 REN INS

Sources for Diabetes Insipidus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....